Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxo Group Limited

Ivan Leo Pinto

Stephen Allan Smith

Deirdre Mary Bernadette Hickey

Colin Andrew Leach

Robert John Ife

Steven James Stanway

Neville Hubert Nicholson

Shahzad Sharooq Rahman

John Liddle

Roderick Alan Porter

Andrew McMurtrie Mason

Richard Leonard Elliott

Ashley Edward Fenwick

Richard Jonathan Daniel Hatley

Deirdre Mary B Hickey

Stephen Allen Smith

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atherosclerosis.

Compounds

The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes

The present invention relates to a xanthine compound derivative which is 3-butyl-8-chloro-1-(3-{5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl}propyl)-3,7-dihydro-1H-purine-2,6-dione: a pharmaceutically acceptable salt thereof, corresponding pharmaceutical formulations, combinations, preparation methods and methods or uses in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

Xanthine derivatives as selective HM74A agonists

The present invention relates to a therapeutically active xanthine derivative compound of formula (I): corresponding pharmaceutical formulations containing, manufacture processes for, methods or uses of such compounds in therapy, in particular for treatment of diseases where under-activation of the HM74A receptor contributes to such diseases or where activation of the HM74A receptor will be beneficial.

Xanthines with HM74A receptor activity

5,6-trimethylenepyrimidin-4-one compounds

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atheroscelerosis.

Pyrimidine compounds

Compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in therapy, in particular for treating atherosclerosis.

Pyrimidinone derivatives and their use in the treatment of atherosclerosis

Pyridinone derivatives for treatment of atherosclerosis

Compound of formula (I): are disclosed in which:

Pyrimidinone compounds of formula (10 are inhibitors of the enzyme Lp-PLAand of use in therapy, in particular for treating atherosclerosis.

Pyrimidinone compounds

A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA and therefore of use in treating atherosclerosis.

Growing community of inventors

Stevenage, United Kingdom

Ivan Leo Pinto